According to GSK, the last time the FDA cleared a new class of antibiotics for uncomplicated UTIs was in 1996, with the approval of fosfomycin. (Last year, the agency approved the drug Pivya for ...
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine ...
The U.S. Food and Drug Administration recently authorized the marketing of 20 nicotine pouch products under the Zyn brand, including flavors like Wintergreen and the "unflavored" Chill. That ...
The FDA approved GSK’s drug for a common type of urinary tract infection in women and adolescent girls. REUTERS/Chris J. Ratcliffe/File Photo GSK is banking on new drugs in its infectious ...
Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 formulation of tesamorelin for injection. The Company ...
President Donald Trump's choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, was confirmed in the Senate on Tuesday. His ...
He will take over leadership of the agency as the FDA has been targeted by sweeping cuts by Elon Musk’s so-called Department of Government Efficiency. Makary said during his confirmation hearing ...
17hon MSN
SS Innovations International (OTCPK:SSII) has received regulatory approvals for its SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine, the company said on Friday. In addition to ...
When they were first introduced, alternate logos for minor-league baseball teams were primarily just meant to be fun. The game changed in 2015, when the Fresno Grizzlies temporarily became the ...
Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...
Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback